Neil Fraser, MD
Internal Medicine · Troy, MINPI 1912966649
Payments from drug & device makers
Across 4,440 payments — averaging $3229.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$9.7M
- Merck$1.1M
- Novartis$1.1M
- Novo Nordisk AS$843K
- Sanofi US Services Inc.$486K
- Pfizer$452K
- plus $610K from 24 others
Across 32 payments — averaging $4684.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$150K
What the payments were for
- Consulting fees$2,75019%
- Travel & lodging$5,16835%
- Food & beverage$6,60845%
- Education$600%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 224 | $9,743,150 |
| Merck | 52 | $1,143,335 |
| Novartis | 28 | $1,063,251 |
| Novo Nordisk AS | 3,685 | $842,874 |
| Sanofi US Services Inc. | 103 | $485,726 |
| Pfizer | 110 | $452,354 |
| Amgen | 50 | $202,746 |
| AstraZeneca | 10 | $127,414 |
| AbbVie | 60 | $124,075 |
| Sanofi Pasteur Inc. | 1 | $55,550 |
| Gilead | 27 | $51,068 |
| Lexicon Pharmaceuticals, Inc. | 1 | $41,098 |
| Amarin Pharma, Inc. | 12 | $5,507 |
| Novo Nordisk | 19 | $749 |
| Abbott | 3 | $304 |
| Astellas Pharma US Inc | 13 | $267 |
| Lilly USA, LLC | 6 | $249 |
| GSK | 3 | $168 |
| Boehringer Ingelheim | 5 | $161 |
| Johnson & Johnson | 2 | $114 |
| Kowa Pharmaceuticals America, Inc. | 11 | $108 |
| Evoke Pharma, Inc. | 1 | $100 |
| Daiichi Sankyo Inc. | 4 | $58 |
| Teva Pharmaceuticals USA, Inc. | 2 | $42 |
| Regeneron Healthcare Solutions, Inc. | 3 | $38 |
| Azurity Pharmaceuticals, Inc. | 1 | $22 |
| Exact Sciences | 1 | $15 |
| Surgenex LLC | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Dynavax Technologies Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,340,582 in reported general payments places this provider in the 95th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 124 | $163,035 |
| TrulicityDulaglutide | 95 | $131,519 |
| MounjaroTirzepatide | 92 | $101,471 |
| OzempicSemaglutide | 72 | $93,070 |
| JardianceEmpagliflozin | 57 | $80,046 |
| XareltoRivaroxaban | 63 | $69,630 |
| FarxigaDapagliflozin Propanediol | 31 | $40,340 |
| JanuviaSitagliptin Phosphate | 22 | $32,877 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $24,649 |
| EntrestoSacubitril/Valsartan | 14 | $21,854 |
| MyrbetriqMirabegron | 18 | $15,774 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $11,577 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 76 | $11,264 |
| Atorvastatin Calcium | 815 | $8,938 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 66 | $8,837 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $249 | $232,990187 claims |
| PfizerEliquis, Paxlovid | $452,354 | $167,246147 claims |
| Novo NordiskOzempic | $749 | $93,07072 claims |
| Boehringer IngelheimJardiance | $161 | $80,04657 claims |
| Johnson & JohnsonXarelto | $114 | $69,63063 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix | $168 | $42,62978 claims |
| AstraZenecaFarxiga | $127,414 | $40,34031 claims |
| MerckJanuvia | $1,143,335 | $32,87722 claims |
| NovartisEntresto | $1,063,251 | $21,85414 claims |
| Astellas Pharma US IncMyrbetriq | $267 | $15,77418 claims |
| AbbVieSynthroid | $124,075 | $4,14261 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Troy
- Jay SandbergTroy$8.3M
- John CaladoTroy$198K
- Ulka VaishampayanAnn Arbor$33.7M
- Jeffrey PottsBay City$14.7M
- Abdulhassan SaadDearborn$11.5M
- Leslie PelkeyGrand Rapids$8.5M
- Ding WangDetroit$6.8M
- Dipenkumar ModiDetroit$4.1M
- Ahmed ArifFlint$4.1M
- Sudipto MukherjeeRoyal Oak$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.